Codex

The Bottom Line from the Web

The biggest web-only update is that Cigna's PBM risk is no longer just a policy overhang. The February 4, 2026 FTC settlement with Express Scripts appears to force concrete operating changes, including moving away from list-price-linked economics, adding outside monitoring, and accelerating the transparency shift management had already started discussing (Reuters, STAT, Bloomberg). The second-biggest web finding is that succession is real but not a clean governance reset: Brian Evanko becomes CEO on July 1, 2026, while David Cordani stays on as executive chair, preserving continuity but also keeping the outgoing CEO in the boardroom (The Cigna Group, PR Newswire).

What Matters Most

FTC settlement turns abstract PBM risk into mandated operating change

Reuters reported that the February 4, 2026 settlement requires Express Scripts to overhaul drug-pricing practices and submit to an independent monitor for three years, while STAT said the FTC believes the consent order could save up to $7 billion in patient out-of-pocket costs over 10 years (Reuters, STAT). Bloomberg added that Express Scripts would change how it calculates formulary pricing, and NCPA said the deal also eliminates spread pricing, decouples rebates and fees from drug list prices, relocates Ascent to the U.S., and imposes 10 years of FTC monitoring (Bloomberg, NCPA).

The rebate-free PBM model is the real business-model transition, not a marketing tweak

Evernorth said Cigna Healthcare's fully insured lives move first in 2027 and the rebate-free design becomes the standard client offering in 2028 (Evernorth, PR Newswire). The web adds two details missing from a simple "transparency" narrative: Healthcare Dive said Cigna still expects comparable pharmacy margins of roughly 4%, but Becker's reported "meaningful" transition cost into 2027, and management commentary summarized by Ticker Report said at least 50% of Evernorth business is expected to adopt the model by year-end 2028 (Healthcare Dive, Becker's Payer Issues, Ticker Report).

CEO succession preserves strategy continuity, but not a full governance reset

The March 3, 2026 announcement makes Brian Evanko CEO effective July 1, 2026 and moves David Cordani to executive chair while also adding Evanko to the board (The Cigna Group, PR Newswire). The outside commentary in this dataset mostly reads the move as continuity rather than rupture, especially because Evanko ran both finance and operations and is widely associated with the Medicare divestiture, but that same continuity means the web does not show a clean break from Cordani-era governance (FinancialContent, Yahoo Finance).

The Medicare exit looks strategic, and the market's current debate has moved elsewhere

Cigna completed the sale of its Medicare Advantage, Medicare Part D, supplemental benefits, and CareAllies businesses to HCSC on March 19, 2025 for about $3.7 billion, with the company saying the proceeds would largely support capital deployment priorities (The Cigna Group, PR Newswire, HCSC). Web commentary now treats that deal as the step that made Cigna a more explicitly services-led company; current investor concern is more about Evernorth margin resilience than about lingering Medicare drag (FinancialContent, Fierce Healthcare).

Medical-cost pressure is real, but the web points to ACA individual plans and stop-loss as the main culprits

The insurance book does not look uniformly broken in the web research. HCI Innovation Group said Cigna Healthcare's 2025 medical care ratio was 84.4%, up 120 basis points year over year mainly because of individual and family plans, while 2026 guidance of 83.7% to 84.7% still supports at least $4.5 billion of Cigna Healthcare pre-tax adjusted income (HCI Innovation Group). That lines up with Fierce Healthcare's reporting that 2025 pressure came from individual and family plans and stop-loss rather than a wholesale deterioration across the commercial book (Fierce Healthcare).

Insider trading is not broadly bullish, aside from one notable Cordani purchase

Quiver's summary of the last six months showed one purchase and three sales: David Cordani bought 4,134 shares for about $999,916, while Brian Evanko sold 5,368 shares, Nicole Jones sold 2,307 shares, and Everett Neville sold 1,719 shares (Quiver Quantitative). The SEC Form 4 aggregation in the local research confirms those trades and dates, including Jones and Neville both selling on March 2, 2026 and Jones' sale being executed under a Rule 10b5-1 plan according to Investing.com (SECForm4, Investing.com).

Sell-side sentiment improved sharply once PBM panic stopped escalating

Benzinga's analyst summary shows a consensus price target of about $365 with the three most recent ratings averaging about $359, implying roughly 29% upside from the quoted price at the time of capture (Benzinga). Bernstein's March 12, 2026 upgrade to Outperform with a $358 target is the clearest sign that at least part of the Street now views the PBM overhang as manageable rather than thesis-breaking (Benzinga, Quiver Quantitative).

The AI claims-denial litigation remains an underappreciated legal and reputational risk

Multiple legal summaries in the dataset say a California federal court on March 31, 2025 allowed part of the class action over Cigna's PxDx algorithm-based denials to proceed, even though some claims were dismissed (PPI Benefits, Digital Healthcare Law, Bloomberg Law). It is not the central valuation driver today, but it reinforces the broader web theme that governance scrutiny around claims handling has not disappeared.

Recent News Timeline

The timeline makes the current setup clear: February was dominated by FTC and earnings resets, while March shifted the debate toward succession, governance, and whether the Street should re-rate the stock after the PBM panic failed to escalate.

What the Specialists Asked

Insider Spotlight

David M. Cordani

Cordani remains the central insider even as he prepares to step down as CEO. The most notable transaction in the recent window is his November 3, 2025 open-market purchase of 4,134 shares for about $999,916, which stands out because it runs against the broader selling pattern in the rest of the executive group (SECForm4, Quiver Quantitative).

The compensation picture is elevated but not obviously accelerating. Quiver's proxy-based estimate puts his 2025 compensation at about $22.9 million, down modestly from the 2024 level of about $23.25 million cited in web coverage of the 2025 proxy cycle (Quiver Quantitative, Becker's Payer Issues).

Brian C. Evanko

Evanko is the insider who matters most for the next chapter because he is both the successor CEO and one of the clearest symbols of continuity. Web reporting consistently frames him as the architect of the Medicare divestiture and a long-time internal operator with finance and business-line credentials, which supports the "continuity candidate" reading of the succession (The Cigna Group, FinancialContent).

His October 3, 2025 sale of 5,368 shares for about $1.61 million is not unusual in isolation, but it means the incoming CEO was a seller, not a buyer, in the recent period (Investing.com, SECForm4).

Nicole S. Jones and Everett Neville

Jones and Neville matter because both sold on March 2, 2026, right after the succession announcement window opened. Jones' 2,307-share sale was explicitly disclosed as being under a Rule 10b5-1 plan adopted on May 8, 2025, which reduces the signal value of that trade on its own, but it still contributes to a broader insider tape that does not show widespread opportunistic buying (Investing.com, SECForm4).

Industry Context

The industry context that matters most is not generic managed-care competition. It is the combination of PBM regulation, transparency pressure, and specialty pharmacy economics. The FTC settlement with Express Scripts shows that U.S. regulators are willing to use consent orders to reshape PBM behavior directly, and the consent order language captured in the Federal Register and industry reporting suggests those changes will matter beyond insulin alone (Federal Register, Goodwin).

At the same time, the web research still points to specialty pharmacy and biosimilars as the strongest underlying support for Evernorth. Managed Healthcare Executive highlighted biosimilar and specialty-pharmacy momentum in the 2025 results, which helps explain why analysts can stay constructive on the stock even while expecting near-term PBM margin pressure (Managed Healthcare Executive, Benzinga).

The competitive disruption cases from Amazon Pharmacy and Cost Plus Drugs appear more thematic than immediate in this dataset. The much more immediate industry force is regulatory redesign of how the big PBMs get paid.